Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review - Scorecard - MDSpire

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • By

  • Xin Shen

  • Jiangnan Yang

  • Yang Du

  • Deyuan Fu

  • June 4, 2026

  • 0 min

Share

Clinical Scorecard: Combination of Adjuvant Chemotherapy and Pembrolizumab for Primary Triple-Negative Neuroendocrine Breast Carcinoma: A Case Study and Review of Existing Literature

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPostmenopausal women with primary triple-negative NEBC, emphasizing the rarity and aggressiveness of the subtype.
Care Setting

Key Highlights

  • Add a highlight regarding the implications of PD-L1 positivity and BRCA1/2 mutation on treatment strategy.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular follow-up with clinical examination, imaging (specify modalities), and serum tumor markers every 3-6 months.

      Risks

        Patient & Prescribing Data

        71-year-old postmenopausal woman with primary triple-negative NEBC.

        Combination of chemotherapy and immunotherapy is a novel approach for this rare subtype.

        Clinical Best Practices

        • Include examples of managing specific treatment-related adverse effects, such as using growth factors for myelosuppression.

        Related Resources & Content

        Original Source(s)

        Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

        • by Xin Shen, Jiangnan Yang, Yang Du, Deyuan Fu

        • June 4, 2026

        Related Content

        Ultrasound-driven mechanical immunomodulation enhances tumor treatment sensitivity: advances from tumor mechanical immunobiology to immunotherapy applications

        Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

        Comprehensive analysis of the TGF-β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation